Cite
Regulatory and HTA Considerations for Development of Real‐World Data Derived External Controls.
MLA
Curtis, Lesley H., et al. “Regulatory and HTA Considerations for Development of Real‐World Data Derived External Controls.” Clinical Pharmacology & Therapeutics, vol. 114, no. 2, Aug. 2023, pp. 303–15. EBSCOhost, https://doi.org/10.1002/cpt.2913.
APA
Curtis, L. H., Sola, M. O., Heidt, J., Saunders, H. P., Walsh, L., Casso, D., Oliveria, S., Mercado, T., Zusterzeel, R., Sobel, R. E., Jalbert, J. J., Mastey, V., Harnett, J., & Quek, R. G. W. (2023). Regulatory and HTA Considerations for Development of Real‐World Data Derived External Controls. Clinical Pharmacology & Therapeutics, 114(2), 303–315. https://doi.org/10.1002/cpt.2913
Chicago
Curtis, Lesley H., Morales, Oriol Sola, Julien Heidt, Hastings, Patrick Saunders, Laura Walsh, Deborah Casso, Susan Oliveria, et al. 2023. “Regulatory and HTA Considerations for Development of Real‐World Data Derived External Controls.” Clinical Pharmacology & Therapeutics 114 (2): 303–15. doi:10.1002/cpt.2913.